Grace Therapeutics, Inc. 8-K

What Happened

• Grace Therapeutics, Inc. (NASDAQ: GRCE) filed a Form 8‑K dated June 18, 2026 to furnish information regarding its results of operations and financial condition under Item 2.02.
• The company attached a press release as Exhibit 99.1 dated June 18, 2026 and included the cover page interactive XBRL file as Exhibit 104. The 8‑K does not report any executive changes or other items beyond the furnished financial information.

Key Details

• Filing date: June 18, 2026 (Form 8‑K).
• Item reported: 2.02 — Results of Operations and Financial Condition (information furnished).
• Exhibits included: 99.1 — Press Release dated June 18, 2026; 104 — Cover Page Interactive Data File (Inline XBRL).
• No Item 5.02 (executive change) or other corporate action was disclosed in this filing.

Why It Matters

• This 8‑K notifies investors that Grace Therapeutics has released updated financial and operational information; investors should read the attached press release for specifics on earnings, revenue, cash position, guidance, or other quarterly results.
• Because the Form 8‑K furnishes (rather than files) the information under Item 2.02, the press release itself is the primary source for the actual numbers and management commentary—review that exhibit and related SEC filings (e.g., 10‑Q/10‑K) for full financial detail before making investment decisions.